NEW YORK (GenomeWeb News) – Beckman Coulter has priced two senior notes offerings and has filed a prospectus to sell up to $250 million worth of common stock, which will help pay for its $780 million acquisition of Olympus' diagnostics business.

The offerings were expected, as Beckman said in late February that it would pay for the acquisition through a combination of around $500 million worth of new debt and roughly $300 million of its common stock.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.